Waystar (WAY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Q1 2026 revenue reached $313.9 million, up 22% year-over-year, with net income of $43.3 million and adjusted EBITDA of $135.4 million, driven by strong subscription growth, AI innovation, and successful integration of Iodine.
Over 99% of revenue is recurring, with net revenue retention at 111% and client count with over $100,000 in trailing twelve-month revenue rising to 1,433, up 15% year-over-year.
AI-powered solutions now account for 40% of new bookings and nearly 40% of revenue, accelerating platform adoption and expanding the addressable market.
Integration of Iodine is ahead of plan, enhancing clinical and financial data convergence, cross-sell opportunities, and AI capabilities.
Launched new AI-powered recoupment solution and Prebill Anomaly Detection, delivering strong early ROI for providers.
Financial highlights
Q1 2026 revenue was $313.9 million, up 22% year-over-year; subscription revenue grew 38% to $172.2 million (55% of total), and volume-based revenue increased 7% to $139.5 million.
Adjusted EBITDA was $135.4 million, up 26% year-over-year, with a 43% margin, slightly above expectations due to favorable revenue mix.
Net income for Q1 2026 was $43.3 million, up 47.9% year-over-year, with a net income margin of 14%.
Unlevered free cash flow was $90.3 million, converting 67% of adjusted EBITDA.
Ended Q1 with $159 million in cash equivalents and $1.5 billion in gross debt; net debt stood at $1.32 billion.
Outlook and guidance
FY 2026 revenue guidance is $1.274–$1.294 billion (midpoint $1.284 billion, 17% year-over-year growth), with adjusted EBITDA of $530–$540 million and a margin expected to remain at 42–43%.
Non-GAAP net income projected at $317–$335 million and diluted non-GAAP EPS expected between $1.59 and $1.68.
Full-year guidance assumes normalized organic revenue growth of ~10% and less seasonality in patient payments.
Q2 sequential growth expected to be flat to 1%, with Q3 at 1–3%.
Sufficient liquidity is anticipated for at least the next 12 months, with ongoing investments in growth and technology.
Latest events from Waystar
- Record revenue, AI innovation, and strong governance mark a transformative year.WAY
Proxy filing17 Apr 2026 - Shareholders will vote on director elections, auditor ratification, and annual say-on-pay frequency.WAY
Proxy filing17 Apr 2026 - Record FY2025 growth, 43% Q4 EBITDA margin, and strong 2026 outlook after Iodine integration.WAY
Q4 202511 Apr 2026 - AI-powered automation streamlines healthcare payments, boosting efficiency and financial outcomes.WAY
Waystar True North Client Conference3 Feb 2026 - Q2 revenue up 20% to $234.5M, 40% EBITDA margin, and improved leverage ratios.WAY
Q2 20242 Feb 2026 - Modern, AI-powered platform drives growth, efficiency, and client wins amid rising cybersecurity focus.WAY
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 revenue up 22% to $240.1M, 40% EBITDA margin, and major debt reduction post-IPO.WAY
Q3 202416 Jan 2026 - AI-driven automation and data integration fuel growth, efficiency, and client satisfaction.WAY
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Cloud-based healthcare payment software drives growth, efficiency, and resilience in a shifting market.WAY
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026